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Abstract 
Neuroblastoma is a clinically heterogenous pediatric 
cancer of the sympathetic nervous system that 
originates from neural crest cells. It is the most 
common extracranial solid tumor in childhood and 
prognosis ranges from spontaneous tumor regression 
to aggressive disease resistant to multimodal 
therapy.  
Prognosis depends on patient characteristics and 
tumor biology that determine risk classification. 
Advancements in therapy reductions are merited for 
low- and intermediate-risk neuroblastoma patients, 
who generally have excellent outcomes. Of the 
patients with high-risk disease, only 50% achieve 
long-term survival, and therapeutic advancements 
are needed.  
Over the past several decades, genomic features such 
as germline mutations, somatic genetic aberrations, 
chromosome copy number, transcriptomics, and 
epigenetics have proven to contribute to the 
pathogenesis of neuroblastoma. The primary 
predisposition genes in familial neuroblastoma are 
ALK and PHOX2B. Sporadic neuroblastoma arises 
with complex pathogenesis, but chromosomal 
abnormalities and single-nucleotide polymorphisms 
have been identified to cooperatively lead to 
oncogenesis.  
These advances have led to new therapeutic 
approaches with the potential to improve outcomes 
for children with neuroblastoma. 
Keywords Neuroblastoma, oncology, pediatrics 
Classification 
Peripheral neuroblastic tumours; are derived from 
developing neuronal cells of the sympathetic 
nervous system and are found mostly (but not 
exclusively) in infants and young children. 
In the text below, we will stick to the well-known 
term neuroblastoma instead of using the more 
precise but less common term peripheral 
neuroblastic tumours. 
Neuroblastoma risk stratification utilizes age, stage, 
histology, MYCN gene amplification status, tumor 
cell ploidy, and segmental chromosomal 
abnormalities (Cohn et al., 2009).  
The International Neuroblastoma Risk Group 
(INRG) classification system stratifies patients into 
low-, intermediate-, and high-risk groups.  
Low- and intermediate-risk patients have excellent 
outcomes and current clinical trials aim to reduce 
therapy-related toxicities.  
High-risk neuroblastoma survival remains poor, 
necessitating new and improved treatment (Pinto et 
al., 2015). 
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Clinics and pathology 
Disease 
 Localisation: Adrenal medulla (50%) and para- and 
prae-vertebral sympathetic ganglia and paraganglia: 
cervical (5%), thoracic (15%), retroperitoneal (25%) 
and pelvic (5%). 
 Metastatic disease: In 50% of patients metastatic 
tumour spread is found at diagnosis. Common sites 
of metastases are: bone marrow, bones, lymph 
nodes, liver and skin. A unique pattern of metastatic 
spread in infants with favourable prognosis is 
mentioned below (under stage MS). 
 Clinical Symptoms: The presenting clinical 
symptoms depend on the primary tumor location as 
well as the regional and metastatic dissemination. An 
abdominal tumor can be associated with discomfort, 
pain, digestive problems, and/or a palpable mass. 
Thoracic tumors are either found coincidentally or 
may cause respiratory distress, dysphagia, and 
circulatory problems. Cervical neuroblastomas can 
cause damage to the cervical ganglion, leading to 
Horner's syndrome. Dumbbell tumors affecting the 
spinal cord and nerve roots can cause radicular pain, 
paraplegia, and dysfunction of bladder or bowel. 
Metastatic disease to the bone marrow or bleeding 
into a large primary tumor can cause anemia and 
thrombocytopenia. Bone metastases can cause pain, 
leading to limping or refusal to bear weight. 
Periorbital bone lesions may cause proptosis and 
bruising (“raccoon eyes”). Liver infiltration can lead 
to coagulopathy and jaundice. Systemic symptoms 
such as fever and weight loss may be present. 
Release of catecholamines by neuroblastoma tumors 
can cause tachycardia, hypertension, and flushing. 
Paraneoplastic presentations occur in a small percent 
of neuroblastoma patients, including opsoclonus 
myoclonus syndrome (OMS) and diarrhea caused by 
the secretion of vasoactive intestinal peptide (VIP). 
Symptoms of OMS include fast, uncontrolled, 
horizontal and vertical eye movements, as well as 
involuntary muscle twitching, occasionally with 
ataxia. 
Differential diagnosis: The differential diagnosis 
varies based on tumor location and clinical 
presentation. For those with abdominal tumors, 
Wilms tumor and hepatoblastoma can be considered. 
Other thoracic tumors such as lymphoma and germ 
cell tumors will generally present in the anterior 
mediastinum whereas neuroblastoma will present in 
the posterior mediastinum along the sympathetic 
ganglia. Neuroblastoma metastatic to the bone 
should be differentiated from osteosarcoma, Ewing 
sarcoma, and chondrosarcoma. Bone marrow 
involvement should be distinguished from leukemia 
or lymphoma. OMS can occur with other conditions 
such as hepatoblastoma, infection, toxin exposures, 
and metabolic derangements. 
 Diagnosis: All patients being evaluated for 
neuroblastoma should have a history and physical 
exam. Routine blood tests include blood counts, 
chemistries, and a hepatic panel. Measurement of the 
urinary catecholamine metabolites vanillylmandelic 
acid (VMA) and homovanillic acid (HVA) can help 
confirm a diagnosis. Confirmation of disease 
requires biopsy (of either primary tumor or bone 
marrow) and histologic evaluation. For tumor 
staging, CT or MRI of the primary tumor and nodal 
sites of metastatic disease is indicated. Patients 
should undergo I123 meta-iodobenzylguanidine 
(MIBG) scintigraphy or PET if MIBG non-avid to 
evaluate for metastatic bone disease, as well as 
bilateral bone marrow aspirates and biopsies to 
determine involvement of that site. 
 
I123 meta-iodobenzylguanidine MIBG scan of newly 
diagnosed patient with neuroblastoma. Bright white areas 
indicate area of neuroblastoma primary in the right adrenal 
gland with numerous bone and bone marrow metastases. 
Embryonic origin 
Neural crest cells of the sympathetic lineage 
(sympathetic neuronal precursor cells). 
Etiology 
The pathogenesis is not fully understood, but it is 
clear that many cytogenetic and molecular factors 
(discussed below) drive the development of 
neuroblastoma. 
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INRG Pre-Treatment Classification Schema (adapted from Cohn et al. 2009) 
 
 
Most neuroblastomas occur sporadically, with only 
1-2% occurring in families in an autosomal 
dominant pattern (Matthay et al., 2016). 
Epidemiology 
Neuroblastoma is the most frequently diagnosed 
tumor in infancy and the most common extracranial 
solid tumor and most common cancer diagnosed 
within the first year of life. These tumors account for 
7-10% of all childhood cancers. The incidence, 
which is almost uniform in industrialized countries, 
is 5-10 per million children per year. The median age 
at diagnosis is approximately 17 months. 50% of 
patients are diagnosed by the age of 2, and 90% of 
patients are diagnosed before 6 years of age. 
Pathology 
The International Neuroblastoma Pathology 
Classification (INPC - Shimada system) groups 
neuroblastic tumors into four histopathologic 
categories according to the degree of cellular 
differentiation into ganglionic cells, 'organoid' 
maturation with the development of a Schwann cell 
stroma, and co-existence of clones of different 
maturity or of distinct aggressiveness:  
 Neuroblastoma (Schwannian stroma-poor)  
 Ganglioneuroblastoma intermixed 
(Schwannian stroma-rich) 
 Ganglioneuroma (Schwannian stroma-
dominant), maturing subtype OR 
Ganglioneuroblastoma, well differentiated 
(Schwannian stroma-rich) 
 Ganglioneuroblastoma nodular 
(composite).  
Two of these categories are further divided into 
subgroups according to cellular differentiation signs, 
i.e. Neuroblastoma into: undifferentiated, poorly 
differentiated and differentiating; and 
Ganglioneuroblastoma into maturing and mature.  
The degree of differentiation and stromal component 
of tumors can be used for prognostic assessment. 
Additionally, the age of the patient at diagnosis 
(below 1.5, between 1.5 and 5 years or over 5 years) 
is included as well as the number of mitotic and 
karyorrhectic (apoptotic) cells in the category of 
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Neuroblastoma and the nodular part of 
Ganglioneuroma nodular. 
Favorable features include: 
 Poorly differentiated or differentiating
neuroblastoma, low or intermediate
mitosis-karyorrhexis index (MKI), and age
≤ 1.5 years
 Differentiating neuroblastoma, low MKI,
and age 1.5 to 5 years
 Ganglioneuroblastoma, intermixed
 Ganglioneuroma
Unfavorable features include: 
 Undifferentiated tumor or high MKI tumor
 Poorly differentiated tumor or intermediate
MKI tumor in patients age 1.5 to 5 years
 Patients ≥ 5 years with any grade of
differentiation or MKI class
 Nodular ganglioneuroblastoma
Prognostic Factors: As neuroblastoma is a 
heterogeneous disease, risk stratification according 
to clinical features of the patient and biologic 
features of the tumor has allowed for an accurate 
assessment of prognosis and risk-adapted therapy. 
To facilitate clinical research and improve the 
outcome of children with neuroblastoma, 
investigators from the major cooperative groups 
developed a consensus pre-treatment International 
Neuroblastoma Risk Group (INRG) classification 
system. The task force collected data on 36 
prognostic variables on 8,800 children enrolled on 
cooperative group studies and identified the seven 
factors that were highly statistically significant and 
also considered clinically relevant (Cohn et al., 
2009).  
-Tumor Stage: 
 -Stage L1: Locoregional tumor not
involving vital structures as defined by the
image-defined risk factors (IDRF) and
confined to one body part
 -Stage L2: Locoregional tumor with
presence of one or more IDRF
 -Stage M: Distant metastatic disease
(except Stage MS)
 -Stage MS: Metastatic disease confined to
skin, liver, and/or bone marrow
-Age at diagnosis: Age <18 months at diagnosis is 
favorable  
-Pathologic risk classification: Categorized into 
favorable and unfavorable based on cell 
differentiation, schwannian cell content in stroma, 
MKI, and age at diagnosis 
-Cytogenetics and molecular genetics: 
Cytogenetic and molecular characteristics known to 
correlate with poor prognosis include MYCN 
amplification, ploidy, and 11q aberration. 
-Somatic Genomic Variations: Multiple 
somatically acquired genomic alterations that 
contribute to tumorigenesis and progression of 
disease have been described. Somatic changes in the 
tumor genome such as gene mutations, loss or gain 
of alleles, and variations in ploidy have been 
identified as important factors in in the development 
of neuroblastoma and contribute to its diverse 
phenotype. 
Treatment 
Patients with low-risk neuroblastoma are often 
managed with surgical resection or, as is being 
evaluated in an ongoing clinical trial 
(NCT01728155), observation alone. Intermediate-
risk patients are treated with chemotherapy (number 
of cycles is dependent on prognostic markers) and 
surgical resection of the primary tumor (Twist et al., 
2019). Low- and intermediate-risk neuroblastomas 
have excellent outcomes and clinical trials aim to 
reduce therapy-related toxicities (Pinto et al., 2015). 
High-risk standard-of-care treatment consists of 
three treatment blocks. The first block, induction, 
includes high-dose chemotherapy and resection of 
the primary tumor. The second block is 
consolidation, which consists of tandem courses of 
myeloablative dose chemotherapy with autologous 
stem-cell rescue and external-beam radiotherapy 
(Park et al., 2019). Lastly, post-consolidation 
therapy includes anti–ganglioside 2 (GD2) 
immunotherapy with cytokines and cis-retinoic acid 
(Yu et al., 2010). Current clinical trials are 
evaluating the addition of MIBG therapy to 
induction (NCT01175356), anti–GD2 to induction 
chemotherapy (NCT01857934), or removing IL2 
from immunotherapy and altering chemotherapy 
regimens (NCT01704716). Refractory and relapsed 
neuroblastoma is common in high-risk patients, 
indicating the need for further research on acquired 
drug and/or clonal resistance. While many patients 
can be salvaged with combination chemotherapy and 
anti-GD2 antibody (Mody et al., 2017), the long-
term outcomes of relapsed neuroblastoma remain 
dismal.  
Neuroblastoma mass screening: Neuroblastoma 
mass screening was attempted in order to identify 
patients in a preclinical stage with the intention to 
decrease mortality. The results obtained by these 
efforts indicated that while the incidence of low-risk 
neuroblastoma increased dramatically, there was no 
decrease in the incidence or mortality of high-risk 
disease, suggesting that screening was ineffective 
and that low-risk and high-risk neuroblastoma are 
two biologically independent entities. 
Evolution 
Special features: As demonstrated by mass 
screening efforts, neuroblastoma tumors range from 
indolent masses that may never be detected to 
rapidly growing and aggressive tumors. Spontaneous 
regression (without cytotoxic treatment) can be 
observed in neuroblastoma diagnosis within the first 
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18 months of life, even with metastatic disease. 
These tumor cells are characterized by distinct 
genomics. Spontaneous maturation of 
neuroblastoma into ganglioneuroblastoma and 
ganglioneuroma can be observed. These 
neuroblastic/ganglionic cells share genetic 
characteristics with spontaneously regressing 
neuroblastomas. Moreover, such tumor cells are 
capable of recruiting non-neoplastic Schwann cells 
from the tumor adjacent tissue.  
Genetics 
Heredity: Most cases of neuroblastoma develop 
sporadically, but familial neuroblastoma accounts 
for 1-2% of all cases (Matthay et al, 2016).  
Familial neuroblastoma presents at a younger age, 
and there is often a family history of the same tumor.  
Its inheritance pattern is most often autosomal 
dominant with incomplete penetrance. 
- PHOX2B: Loss-of-function mutations in paired-
like homeobox 2B (PHOX2B) were the first 
discovered neuroblastoma predisposition genes. 
PHOX2B mutations are responsible for of 6-10% of 
familial neuroblastoma cases. These mutations also 
occur in approximately 2% of sporadic 
neuroblastoma cases (Trochet et al., 2004). 
- ALK: In 2008, the anaplastic lymphoma kinase 
gene (ALK) was identified as the major familial 
neuroblastoma predisposition gene (Mossé et al., 
2008). Three missense mutations in in ALK 
(R1192P, R1275Q, G1128A) were found to be 
present in most familial neuroblastoma cases 
identified. ALK mutations are also present in 10-
12% of cases of sporadic neuroblastoma.  
- KIF1B: KIF1B is a tumor suppressor gene that is 
likely involved in the development of neural crest 
tumors.  
Germline mutations in KIF1B have been found in 
patients who have developed neuronal tumors, 
including neuroblastoma and pheochromocytoma 
(Schlisio et al., 2008; Barr and Applebaum, 2018). 
- Other cancer predisposition syndromes: While the 
mutations in PHOX2B, ALK, and KIF1B are 
specific for predisposition to developing 
neuroblastoma, there are several syndromes that can 
lead to the development of neuroblastoma including 
RAS pathway mutations (Costello syndrome, 
Noonan syndrome, neurofibromatosis type I, and 
congenital central hypoventilation syndrome, Li-
Fraumeni syndrome, ROHHAD syndrome (rapid-
onset obesity with hypothalamic dysfunction, 
hypoventilation, autonomic dysregulation), 
Wiedemann-Beckwith syndrome, Weaver 
syndrome, and Familial 
Paraganglioma/Pheochromocytoma. 
 
Sporadic (Nonfamilial) Neuroblastoma 
Sporadic neuroblastoma is recognized to be a 
complex genetic disease. Large genome-wide 
association studies (GWAS) have identified 
common single nucleotide polymorphisms that 
influence neuroblastoma susceptibility and 
phenotype. 
- BARD1 contains one of the most replicated signals. 
It has generally been thought of as a tumor 
suppressor, but in neuroblastoma, risk alleles are 
associated with increased expression of BARD1, 
which promotes growth (Capasso et al., 2009).  
-LMO1 is a neuroblastoma oncogene and 
polymorphisms in the gene are associated with the 
development of high risk, clinically aggressive 
disease (Wang et al., 2011). 
- LIN28B polymorphisms are strongly correlated to 
with predisposition to high-risk neuroblastoma. 
Variants in HACE1, TP53 have also been identified 
(Diskin et al., 2016). 
- Variants in DUSP12 (1q23), HSD17B12 (11p11), 
DDX4/IL31RA (5q11.2) are associated with low-
risk neuroblastoma (Nguyen et al., 2011). 
- Variants in CASC15, NBAT1 (6p22) influence 
susceptibility to high-risk neuroblastoma (Russell et 
al., 2015).  
- Polymorphisms in KIF15 are associated with the 
development of MYCN amplified neuroblastoma 
(Hungate et al., 2017) and those in MMP20 are 
associated with somatic 11q deletion (Chang et al., 
2017). 
Cytogenetics 
Whole chromosome involvement: Ploidy (DNA 
index) is a significant prognostic marker of patient 
outcome, and it is a component of the INRG 
classification system. Hyperdiploid tumors (DNA 
index >1) occur in about 66% of patients with 
neuroblastoma and are associated with lower risk 
disease and favorable outcomes (Look et al., 1991).  
 Segmental chromosomal aberrations: Tumors 
with segmental and subsegmental chromosomal 
aberrations have been found to be associated with 
high-risk disease. Additionally, new segmental 
aberrations have often been found at time of relapse.  
The most common alterations are gain of 
chromosomes 2p, which is the location of the 
MYCN oncogene; 17q gain; 1p loss of 
heterozygosity (LOH); and 11q loss (Schleiermacher 
et al., 2012; Bown, 2001). 1p LOH is found primarily 
in MYCN amplified tumors whereas loss of 11q is 
correlated with non-MYCN amplified high-risk 
disease (Maris et al., 2000; Depuydt et al., 2018).  
2p24 Amplification-(MYCN): The MYCN 
oncogene on chromosome 2p24 encodes a  
transcription factor that is known to cause malignant 
transformation. Amplification of the MYCN gene is 
noted in 20% of all primary neuroblastoma tumors. 
It is present in 50% of all high-risk tumors, and it is 
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associated with aggressive disease and poor 
prognosis (Brodeur et al., 1984). MYCN 
amplification is used as a biomarker for risk 
stratification in the INRG classification system 
(Cohn et al., 2009).  
17q gain: The gain of the distal portion of 
chromosome 17q is the most common copy number 
aberration in neuroblastoma. It is present in 50% of 
primary neuroblastomas, primarily those that are 
otherwise classified as high-risk (Bown et al., 1999).  
1p LOH: LOH at chromosome 1p36 correlates with 
MYCN-amplification, metastatic disease, and older 
age. It is present in 23-35% of primary 
neuroblastoma tumors (Maris et al., 2000).  
11q loss: occurs in about 33% of neuroblastomas, 
primarily non-MYCN-amplified, high-risk tumors. 
Despite significant research efforts, no confirmed 
driver tumor suppressors have been identified on 1p 
or 11q (Attiyeh et al., 2005).  
 
Genes involved and 
proteins 
Note on Somatic Mutations 
ALK: Genetic missense alterations (most commonly 
at R1275, F1174, and F1245) or gene amplification 
events within anaplastic lymphoma kinase (ALK) 
can occur. It is the gene that is most commonly 
mutated in neuroblastoma and inhibition of ALK 
signaling with crizotinib or newer generation ALK 
inhibitors are being tested in late phase trials (Bresler 
et al., 2014).  
ATRX: Loss-of-function mutations or deletions in 
the RNA helicase alpha-thalassemia/mental 
retardation syndrome X-linked (ATRX) have been 
observed in neuroblastoma (10% of cases) and are 
often found in older patients (age at diagnosis >5). 
ATRX plays a role in chromatin remodeling, 
nucleosome assembly, and telomere maintenance. 
ATRX mutations are mutually exclusive with 
MYCN-amplification and TERT mutations (Pugh et 
al., 2013).  
TERT: Genomic rearrangements in telomerase 
reverse transcriptase (TERT), a target of MYCN, can 
lead to neuroblastoma. It has been proposed that all 
neuroblastomas need a pathway to activate TERT or 
bypass the pathway via ATRX mutation (Valentijn 
et al., 2015). 
ALK (Anaplastic Lymphoma Kinase) 
Location 2p23.1 
Note The major cause of familial neuroblastoma is  
heritable gain-of-function mutations of ALK. ALK 
mutations are also present in 10-12% of cases of 
sporadic neuroblastoma.  
It is the gene that is most commonly mutated in 
neuroblastoma and inhibition of ALK signaling with 
crizotinib or newer generation ALK inhibitors are 
being tested in late phase trials. 
Protein Cell surface receptor tyrosine kinase  
Germinal mutation Three missense mutations in in 
ALK (R1192P, R1275Q, G1128A) were found to be 
present in most familial neuroblastoma cases 
Somatic mutation Genetic missense alterations 
(most commonly at R1275, F1174, and F1245) or 
gene amplification events. 
MYCN 
Location 2p24 
Note Amplification of the MYCN gene is noted in 
20% of all primary neuroblastoma tumors.  
It is present in 50% of all high-risk tumors, and it is 
associated with aggressive disease and poor 
prognosis (Brodeur et al., 1984).  
MYCN amplification is used as a biomarker for risk 
stratification in the INRG classification system.  
The oncogene is either amplified in form of acentric 
double minute chromosomes (dmin) or 
chromosomally integrated as homogeneously 
staining regions (hsr). 
Protein Nuclear protein; helix-loop-helix and a 
leucine zipper domain; transcription factor 
Somatic mutation: Amplification  
ATRX (alpha-thalassemia/mental 
retardation syndrome X-linked) 
Location Xq21.1 
Note Loss-of-function mutations or deletions in 
ATRX have been observed in neuroblastoma (10% 
of cases) and are often found in older patients (age at 
diagnosis >5 years).  
ATRX plays a role in chromatin remodeling, 
nucleosome assembly, and telomere maintenance. 
ATRX mutations are mutually exclusive with 
MYCN-amplification and TERT mutations. 
Protein RNA helicase. 
Somatic mutation Loss of function alterations 
(mutations, multi-exon deletions).  
TERT (telomerase reverse 
transcriptase)  
Location 5p15.33 
Note Genomic rearrangements in TERT, a target of 
MYCN, can lead to neuroblastoma.  
It has been proposed that all neuroblastomas need a 
pathway to activate TERT or bypass the pathway via 
ATRX mutation. 
Protein Subunit of the enzyme telomerase. 
Somatic mutation Rearrangements and copy number 
mutations. 
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